

## FORM 7

### **MONTHLY PROGRESS REPORT**

Name of Listed Issuer: Cognetivity Neurosciences Ltd. (the "Issuer").

Trading Symbol: CGN

Number of Outstanding Listed Securities: 70,676,596

Date: February 28, 2021

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

#### **Report on Business**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Cognetivity Neurosciences Ltd.(the "Company" or "Cognetivity") is developing a platform for the early stage detection of Alzheimer's, dementia, and other conditions involving cognitive impairment. The CompaFny is developing an effective screening tool, to be used by clinical practitioners to allow patients

suffering from cognitive impairment to be referred into the appropriate treatment pathway earlier than is possible using current screening tools, in order to allow more effective treatment. The Company confirmed that its integrated Cognitive Assessment (ICA) software has been approved as a CE-marked medical device.

2. Provide a general overview and discussion of the activities of management.

Management was focusing on the full implementation of substantial quality systems, regulatory processes, and the final design and approval of a major clinical study.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

No new products or services have been offered, nor any new assets acquired in the last month.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

No products or services were discontinued during the month.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Not applicable

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not applicable

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not applicable

8. Describe the acquisition of new customers or loss of customers.

Not applicable

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

Cognetivity has further developed its software and technical infrastructure in preparation for a major validation study and subsequent commercial release.

In addition, the Company's Integrated Cognitive Assessment (ICA) software has been approved as a CE-marked medical device.

The Company has also developed a novel smartphone app focused on the personalised tracking and management of cognitive performance.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Not applicable

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not applicable

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Not applicable

14. Provide details of any securities issued and options or warrants granted.

| Security | Number Issued | Details of Issuance                                                                   | Use of Proceeds <sup>(1)</sup>                       |
|----------|---------------|---------------------------------------------------------------------------------------|------------------------------------------------------|
| Shares   | 138,889       | In February, 2021, 138,889 warrants were exercised at exercised price of \$0.25/share | The gross proceeds is \$34,722. The proceeds will be |

|        |        |                                                                                     |                                                                                                                                                                           |
|--------|--------|-------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|        |        |                                                                                     | used for product development, clinical validation, quality and regulatory, business development and working capital.                                                      |
| Shares | 50,000 | In February, 2021, 50,000 options were exercised at exercised price of \$0.43/share | The gross proceeds is \$21,500. The proceeds will be used for product development, clinical validation, quality and regulatory, business development and working capital. |

*(1) State aggregate proceeds and intended allocation of proceeds.*

15. Provide details of any loans to or by Related Persons.

Not applicable

16. Provide details of any changes in directors, officers or committee members.

Not applicable

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

There has been a noticeable increasing awareness of the importance of early diagnosis in dementia, one of the Company's main target market, with the release of a major study highlighting the economic importance of this (by the Alzheimer's Association) and an ongoing demonstrated need in healthcare systems (for example the UK's NHS) leading to increasing calls for a technology solution that solves this issue. The Company's management believes that the environment for the Company's platform continues to be favourable for wide adoption of its services.

There was a global outbreak of COVID-19 (coronavirus), which has had a significant impact on businesses through the restrictions put in place by the Canadian, provincial and municipal governments regarding travel, business operations and isolation/quarantine orders. At this time, it is unknown the extent of

the impact the COVID-19 outbreak may have on the Company as this will depend on future developments that are highly uncertain and that cannot be predicted with confidence. These uncertainties arise from the inability to predict the ultimate geographic spread of the disease, and the duration of the outbreak, including the duration of travel restrictions, business closures or disruptions, and quarantine/isolation measures that are currently, or may be put, in place by Canada and other countries to fight the virus.

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated March 1, 2021

Denise Lok  
Name of Director or Senior  
Officer

*“Denise Lok”*

\_\_\_\_\_  
Signature

CFO and Corporate Secretary  
Official Capacity

|                                                                                  |                                                           |                                          |
|----------------------------------------------------------------------------------|-----------------------------------------------------------|------------------------------------------|
| <b><i>Issuer Details</i></b><br>Name of Issuer<br>Cognetivity Neurosciences Ltd. | For Month<br>End<br>February 28,<br>2021                  | Date of Report<br>YY/MM/DD<br>2021/03/01 |
| Issuer Address<br>Suite 2250, 1055 W. Hastings Street                            |                                                           |                                          |
| City/Province/Postal Code<br>Vancouver/BC/V6E 2E9                                | Issuer Fax No.<br>(778)329-9361                           | Issuer Telephone No.<br>(604)688-9588    |
| Contact Name<br>Denise Lok                                                       | Contact<br>Position:<br>CFO and<br>Corporate<br>Secretary | Contact Telephone No.<br>(604)688-9588   |

|                                                        |                  |
|--------------------------------------------------------|------------------|
| Contact Email Address<br>denise.lok@barongroupintl.com | Web Site Address |
|--------------------------------------------------------|------------------|